The relationship between diabetes and risk of heart failure has been described in previous
trials, releasing the importance of the hyperglycemic state that, added to other risk factors, favors
the development of coronary heart disease. The mechanism by which, in the absence of hypertension,
obesity and/or dyslipidemia, diabetic patients develop cardiomyopathy has been less
Recently, the Sodium Glucose Co-transporter type 2 inhibitors (SGLT2 inhibitors) used for the
treatment of heart failure patients with or without diabetes has been a breakthrough in the field of
This review describes the established pathophysiology of diabetic cardiomyopathy and SGLT2 inhibitors,
their mechanisms of action, and benefits in this group of patients.